Clinical trials: Esomeprazole
Erosive Esophagitis
Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
To investigate the impact of initial treatment duration (4-week versus 8-week)of Esomeprazole (40mg) on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
- Trial name
- NCT01874535
- Testing
- Esomeprazole 40 mg
- Where
- Taiwan
- Volunteers
- 408 people
- Sponsor
- Chang Gung Memorial Hospital
Gastroesophageal Reflux Disease (GERD)
Phase 3/Safety & Efficacy of Esomeprazole in Infants
The purpose of this study is to look at the improvement of a once a day dose of esomeprazole for reducing the signs and symptoms of infants with gastroesophageal reflux disease (GERD).
- Trial name
- NCT00468559
- Testing
- Open Label Run In Esomeprazole, Double Blind Esomeprazole
- Where
- 25 sites in United States, France and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Implementation of PPI Medication PGX Testing
Using genetic information about the individual to pick the right drug for the right disease at the right dose defines personalized medicine.
- Trial name
- PGX (NCT02794844)
- Testing
- Genotype Guided PPI Dosing
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Nemours Children's Clinic
Homeostasis, Bone and Bones
Effect of Dexlansoprazole on Bone Homeostasis
The purpose of this study is to evaluate the effect of dexlansoprazole modified release (MR), once daily (QD), on bone homeostasis.
- Trial name
- NCT01216293
- Testing
- Dexlansoprazole, Esomeprazole
- Where
- 12 sites in United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Takeda
Familial Hypercholesterolemia
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
The primary objective of this study is to determine the efficacy of once-daily rosuvastatin in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day 0) to the end of the 12-week double-blind…
- Trial name
- NCT00355615
- Testing
- Rosuvastatin
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 173 people
- Sponsor
- AstraZeneca
Juvenile Idiopathic Arthritis (JIA)
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
- Trial name
- NCT01544114
- Testing
- VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20
- Where
- 17 sites in United States
- Volunteers
- 46 people
- Sponsor
- Amgen
GERD
Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients
The purpose of this study is to assess the difference between esomeprazole and placebo in the treatment of signs and symptoms as observed by 8-hour video and cardiorespiratory monitoring in neonatal patients.
- Trial name
- NCT00427635
- Testing
- Esomeprazole
- Where
- 3 sites in Australia, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Reflux Esophagitis, Gastric Ulcer
A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer
This is an open label, parallel group, multi-centre, phase III study to assess the safety and efficacy of D961H in maintenance therapy following initial healing therapy in Japanese paediatric patients with reflux esophagitis, and…
- Conditions
- Reflux Esophagitis, Gastric Ulcer, Duodenal Ulcer
- Trial name
- NCT03553563
- Testing
- D961H capsule 10mg, D961H sachet 10mg
- Where
- 15 sites in Japan
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Peptic Ulcer
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.
- Trial name
- NCT01138969
- Testing
- esomeprazole
- Where
- Taiwan
- Volunteers
- 165 people
- Sponsor
- Kaohsiung Veterans General Hospital.